Protein tyrosine phosphatase 1B (PTP1B) function, structure, and inhibition strategies to develop antidiabetic drugs

IF 3.5 4区 生物学 Q1 Biochemistry, Genetics and Molecular Biology
Andrea Coronell-Tovar, Juan P. Pardo, Adela Rodríguez-Romero, Alejandro Sosa-Peinado, Luz Vásquez-Bochm, Patricia Cano-Sánchez, Laura Iliana Álvarez-Añorve, Martin González-Andrade
{"title":"Protein tyrosine phosphatase 1B (PTP1B) function, structure, and inhibition strategies to develop antidiabetic drugs","authors":"Andrea Coronell-Tovar,&nbsp;Juan P. Pardo,&nbsp;Adela Rodríguez-Romero,&nbsp;Alejandro Sosa-Peinado,&nbsp;Luz Vásquez-Bochm,&nbsp;Patricia Cano-Sánchez,&nbsp;Laura Iliana Álvarez-Añorve,&nbsp;Martin González-Andrade","doi":"10.1002/1873-3468.14901","DOIUrl":null,"url":null,"abstract":"<p>Tyrosine protein phosphatase non-receptor type 1 (PTP1B; also known as protein tyrosine phosphatase 1B) is a member of the protein tyrosine phosphatase (PTP) family and is a soluble enzyme that plays an essential role in different physiological processes, including the regulation of metabolism, specifically in insulin and leptin sensitivity. PTP1B is crucial in the pathogenesis of type 2 diabetes mellitus and obesity. These biological functions have made PTP1B validated as an antidiabetic and anti-obesity, and potentially anticancer, molecular target. Four main approaches aim to inhibit PTP1B: orthosteric, allosteric, bidentate inhibition, and <i>PTPN1</i> gene silencing. Developing a potent and selective PTP1B inhibitor is still challenging due to the enzyme's ubiquitous expression, subcellular location, and structural properties. This article reviews the main advances in the study of PTP1B since it was first isolated in 1988, as well as recent contextual information related to the PTP family to which this protein belongs. Furthermore, we offer an overview of the role of PTP1B in diabetes and obesity, and the challenges to developing selective, effective, potent, bioavailable, and cell-permeable compounds that can inhibit the enzyme.</p>","PeriodicalId":12142,"journal":{"name":"FEBS Letters","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/1873-3468.14901","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FEBS Letters","FirstCategoryId":"99","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/1873-3468.14901","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Tyrosine protein phosphatase non-receptor type 1 (PTP1B; also known as protein tyrosine phosphatase 1B) is a member of the protein tyrosine phosphatase (PTP) family and is a soluble enzyme that plays an essential role in different physiological processes, including the regulation of metabolism, specifically in insulin and leptin sensitivity. PTP1B is crucial in the pathogenesis of type 2 diabetes mellitus and obesity. These biological functions have made PTP1B validated as an antidiabetic and anti-obesity, and potentially anticancer, molecular target. Four main approaches aim to inhibit PTP1B: orthosteric, allosteric, bidentate inhibition, and PTPN1 gene silencing. Developing a potent and selective PTP1B inhibitor is still challenging due to the enzyme's ubiquitous expression, subcellular location, and structural properties. This article reviews the main advances in the study of PTP1B since it was first isolated in 1988, as well as recent contextual information related to the PTP family to which this protein belongs. Furthermore, we offer an overview of the role of PTP1B in diabetes and obesity, and the challenges to developing selective, effective, potent, bioavailable, and cell-permeable compounds that can inhibit the enzyme.

Abstract Image

蛋白酪氨酸磷酸酶 1B (PTP1B) 的功能、结构和开发抗糖尿病药物的抑制策略。
酪氨酸蛋白磷酸酶非受体 1 型(PTP1B,又称蛋白酪氨酸磷酸酶 1B)是蛋白酪氨酸磷酸酶(PTP)家族的成员,是一种可溶性酶,在不同的生理过程中发挥着重要作用,包括调节新陈代谢,特别是调节胰岛素和瘦素的敏感性。PTP1B 在 2 型糖尿病和肥胖症的发病机制中至关重要。这些生物功能使 PTP1B 成为抗糖尿病、抗肥胖以及潜在的抗癌分子靶点。抑制 PTP1B 的方法主要有四种:正交抑制、异位抑制、双柄抑制和 PTPN1 基因沉默。由于PTP1B酶的表达、亚细胞位置和结构特性无处不在,因此开发强效和选择性的PTP1B抑制剂仍具有挑战性。本文回顾了自 1988 年首次分离出 PTP1B 以来对其研究的主要进展,以及与该蛋白所属的 PTP 家族有关的最新背景信息。此外,我们还概述了 PTP1B 在糖尿病和肥胖症中的作用,以及开发能抑制该酶的选择性、有效、强效、生物可用性和细胞渗透性化合物所面临的挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
FEBS Letters
FEBS Letters 生物-生化与分子生物学
CiteScore
7.00
自引率
2.90%
发文量
303
审稿时长
1.0 months
期刊介绍: FEBS Letters is one of the world''s leading journals in molecular biology and is renowned both for its quality of content and speed of production. Bringing together the most important developments in the molecular biosciences, FEBS Letters provides an international forum for Minireviews, Research Letters and Hypotheses that merit urgent publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信